[Adjuvants]

Area of Science:

• Immunology
• Allergology
• Vaccinology

Background:

• Specific immunotherapy (SIT) is the only curative treatment for allergic disorders, yet its utilization remains low, with only 5% of eligible patients receiving it.
• There is a significant need for improved SIT formulations that offer enhanced efficacy with fewer administrations.
• Adjuvants, molecules that modify immune responses, are widely used in vaccine technology to boost antigen immunogenicity.

Purpose of the Study:

• To highlight the limitations of current specific immunotherapy (SIT) uptake.
• To underscore the need for advanced SIT formulations.
• To introduce the potential role of adjuvants in enhancing SIT efficacy and delivery.

Main Methods:

• Review of existing literature on specific immunotherapy (SIT) and adjuvant technology.
• Analysis of the mechanisms by which adjuvants can modulate immune responses to allergens.
• Exploration of adjuvant applications in vaccine development for insights into SIT enhancement.

Main Results:

• Specific immunotherapy (SIT) demonstrates proven efficacy for various allergens but suffers from low patient adoption.
• Adjuvants can potentially enhance SIT by retarding allergen release, modulating immune responses, or acting as delivery vectors.
• Adjuvants offer a promising strategy to improve the safety and efficacy of SIT, potentially reducing the number of required administrations.

Conclusions:

• Adjuvants represent a key area for innovation in developing more effective and accessible specific immunotherapy (SIT) treatments.
• Further research into adjuvant-based SIT formulations could significantly increase treatment efficacy and patient compliance.
• Optimizing SIT with adjuvants is essential to meet the urgent demand for improved curative therapies for allergic diseases.